| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 |
| 13 Nov 2026 | QUARTERLY REPORT |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate |
| 10 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s... |
| 06 Nov 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the l... |
| 03 Nov 2026 |
Form 3: Horn-Warnock Stephanie, CFO, Treasurer, & Corp Sec.
No securities owned |
| 02 Nov 2026 |
Form 4: Frederick John W., Director
Granted 25,000 Stock Option (right to buy) |
| 02 Nov 2026 |
Form 3: Frederick John W., Director
Holds 8,000 shares of Common Stock |
| 02 Nov 2026 | FORM ARS |
| 30 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Chief Financial Officer and Principal Financial and Accounting Officer |
| 26 Oct 2026 |
Proxy statement: annual meeting on November 9, 2026
CEO pay $2.3M, up 23% |
| 20 Oct 2026 | CURRENT REPORT |
| 20 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Brisbane, CA, October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, ... |
| 16 Oct 2026 | PRELIMINARY PROXY STATEMENT |
| 14 Oct 2026 | D |
| 02 Oct 2026 |
Form 4: Smith Nancy Freda, Director
Granted 25,000 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 3: Smith Nancy Freda, Director
No securities owned |
| 02 Oct 2026 | PROSPECTUS |
| 01 Oct 2026 | EFFECT |
Loading...